Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Rural Cameroon study indicates need to double HIV treatment success, monitor outcomes in west, central Africa to control epidemic
Researchers cite critical need for stronger capacities in remote areas to find treatment resistance, failure The numbers of people who are receiving antiretroviral treatment HIV in remote […]
The following is a guest post by Jessica Taaffe, PhD In the current environment of limited tuberculosis research funding, TB research can benefit significantly from data-centric […]
Last June, a Perspective piece in the New England Journal of Medicine noted the critical place that the World Health Organization’s list of Essential Medicines had […]
A few days after the White House released an outline of budget priorities, that included a nearly 20 percent cut to medical research funding, and elimination […]